Table of Contents Author Guidelines Submit a Manuscript
Journal of Toxicology
Volume 2014, Article ID 583494, 10 pages
http://dx.doi.org/10.1155/2014/583494
Research Article

Chlorogenic and Caftaric Acids in Liver Toxicity and Oxidative Stress Induced by Methamphetamine

1Medical Physiology Department, Medical Research Division, National Research Centre, El-Buhouth Street, Dokki, Giza 12622, Egypt
2Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), No. 6 Tingkat 1, Persiaran Seksyen 4/9, Bandar Putra Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
3Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo 11787, Egypt

Received 8 May 2014; Revised 3 July 2014; Accepted 8 July 2014; Published 20 July 2014

Academic Editor: Anthony DeCaprio

Copyright © 2014 Khaled M. M. Koriem and Rowan E. Soliman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Office of Applied Studies, “Primary methamphetamine/amphetamine treatment admissions: 1992–2002,” The DASIS Report, Substance Abuse & Mental Health Services Administration, 2004. View at Google Scholar
  2. NSDUH Report, Methamphetamine Use, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, Md, USA, 2007.
  3. Office of Applied Studies, “Emergency Department Trends from Drug Abuse Warning Network, Final Estimates 1995-2002,” DHHS Publication SMA 03-3780, DAWN Series D-24, Substance Abuse and Mental Health Services Administration, Rockville, Md, USA, 2003. View at Google Scholar
  4. R. Gonzales, L. Mooney, and R. A. Rawson, “The methamphetamine problem in the United States,” Annual Review of Public Health, vol. 31, pp. 385–398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. R. Richards, E. B. Johnson, R. W. Stark, and R. W. Derlet, “Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study,” The American Journal of Emergency Medicine, vol. 17, no. 7, pp. 681–685, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Shima, I. Miyawaki, K. Bando et al., “Influences of methamphetamine-induced acute intoxication on urinary and plasma metabolic profiles in the rat,” Toxicology, vol. 287, no. 1–3, pp. 29–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. L. Jones and K. J. Simpson, “Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 2, pp. 129–133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Carvalho, F. Remião, M. E. Soares, R. Catarino, G. Queiroz, and M. L. Bastos, “d-Amphetamine-induced hepatotoxicity: Possibie contribution of catecholamines and hyperthermia to the effect studied in isolated rat hepatocytes,” Archives of Toxicology, vol. 71, no. 7, pp. 429–436, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Kamijo, K. Soma, M. Nishida, A. Namera, and T. Ohwada, “Acute liver failure following intravenous methamphetamine,” Veterinary and Human Toxicology, vol. 44, no. 4, pp. 216–217, 2002. View at Google Scholar · View at Scopus
  10. L. J. Mooney, S. Glasner-Edwards, R. A. Rawson, and W. Ling, “Medical effects of methamphetamine use,” in Methamphetamine Addiction: From Basic Science to Treatment, J. M. Roll, R. A. Rawson, W. Ling, and S. Shoptaw, Eds., pp. 117–142, The Guilford Press, New York, NY, USA, 2009. View at Google Scholar
  11. Q. Yu, D. F. Larson, and R. R. Watson, “Heart disease, methamphetamine and AIDS,” Life Sciences, vol. 73, no. 2, pp. 129–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. E. Albertson, R. W. Derlet, and B. E. van Hoozen, “Methamphetamine and the expanding complications of amphetamines,” Western Journal of Medicine, vol. 170, no. 4, pp. 214–219, 1999. View at Google Scholar · View at Scopus
  13. S. Darke, S. Kaye, R. McKetin, and J. Duflou, “Major physical and psychological harms of methamphetamine use,” Drug and Alcohol Review, vol. 27, no. 3, pp. 253–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. D. Homer, T. M. Solomon, R. W. Moeller, A. Mascia, L. DeRaleau, and P. N. Halkitis, “Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications,” Psychological Bulletin, vol. 134, no. 2, pp. 301–310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Scott, S. P. Woods, G. E. Matt et al., “Neurocognitive effects of methamphetamine: a critical review and meta-analysis,” Neuropsychology Review, vol. 17, no. 3, pp. 275–297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. E. Zweben, J. B. Cohen, D. Christian et al., “Psychiatric symptoms in methamphetamine users,” The American Journal on Addictions, vol. 13, no. 2, pp. 181–190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Glasner-Edwards, P. Marinelli-Casey, M. Hillhouse, A. Ang, L. J. Mooney, and R. Rawson, “Depression among methamphetamine users: association with outcomes from the methamphetamine treatment project at 3-year follow-up,” Journal of Nervous and Mental Disease, vol. 197, no. 4, pp. 225–231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. W. Meredith, C. Jaffe, K. Ang-Lee, and A. J. Saxon, “Implications of chronic methamphetamine use: a literature review,” Harvard Review of Psychiatry, vol. 13, no. 3, pp. 141–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. R. C. Callaghan, J. K. Cunningham, P. Allebeck et al., “Methamphetamine use and schizophrenia: a population-based cohort study in California,” The American Journal of Psychiatry, vol. 169, no. 4, pp. 389–396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. R. C. Callaghan, J. K. Cunningham, J. Sykes, and S. J. Kish, “Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs,” Drug and Alcohol Dependence, vol. 120, no. 1–3, pp. 35–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Tokunaga, S. Kubo, A. Ishigami, T. Gotohda, and O. Kitamura, “Changes in renal function and oxidative damage in methamphetamine-treated rat,” Legal Medicine, vol. 8, no. 1, pp. 16–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Duh, Y. Tu, and G. Yen, “Antioxidant activity of water extract of haring jury (Chrysanthemum morifolium Ramat),” LWT-Food Science and Technology, vol. 32, no. 5, pp. 269–277, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Büyükokuroğlu, I. Gülçin, M. Oktay, and O. I. Küfrevioğlu, “In vitro antioxidant properties of dantrolene sodium,” Pharmacological Research, vol. 44, pp. 491–495, 2001. View at Google Scholar
  24. M. T. Shrem and P. N. Halkitis, “Methamphetamine abuse in the United States: contextual, psychological and sociological considerations,” Journal of Health Psychology, vol. 13, no. 5, pp. 669–679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. Newman, G. M. Cragg, and K. M. Snader, “Natural products as sources of new drugs over the period 1981–2002,” Journal of Natural Products, vol. 66, no. 7, pp. 1022–1037, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. M. P. Gonthier, C. Remesy, A. Scalbert et al., “Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro,” Biomedicine and Pharmacotherapy, vol. 60, no. 9, pp. 536–540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. S. Meyer, J. L. Donovan, D. A. Pearson, A. L. Waterhouse, and E. N. Frankel, “Fruit hydroxycinnamic acids inhibit low density lipoprotein oxidation in vitro,” Journal of Agricultural and Food Chemistry, vol. 46, no. 5, pp. 1783–1787, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. L. R. Fukumoto and G. Mazza, “Assessing antioxidant and prooxidant activities of phenolic compounds,” Journal of Agricultural and Food Chemistry, vol. 48, no. 8, pp. 3597–3604, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Kerry and C. Rice-Evans, “Peroxynitrite oxidises catechols to o-quinones,” FEBS Letters, vol. 437, no. 3, pp. 167–171, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Bassil, D. P. Makris, and P. Kefalas, “Oxidation of caffeic acid in the presence of L-cysteine: isolation of 2-S-cysteinylcaffeic acid and evaluation of its antioxidant properties,” Food Research International, vol. 38, no. 4, pp. 395–402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Zhao, J. Wang, O. Ballevre, H. Luo, and W. Zhang, “Antihypertensive effects and mechanisms of chlorogenic acids,” Hypertension Research, vol. 35, no. 4, pp. 370–374, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Shen, R. Qi, J. Zhang et al., “Chlorogenic acid inhibits LPS-induced microglial activation and improves survival of dopaminergic neurons,” Brain Research Bulletin, vol. 88, no. 5, pp. 487–494, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. G. M. Raso, M. Pacilio, G. di Carlo, E. Esposito, L. Pinto, and R. Meli, “In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum,” Journal of Pharmacy and Pharmacology, vol. 54, no. 10, pp. 1379–1383, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Barrett, “Medicinal properties of Echinacea: a critical review,” Phytomedicine, vol. 10, no. 1, pp. 66–86, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Gao, Y. Lin, G. Liang, B. Yu, and Y. Gao, “Comparative pharmacokinetic study of chlorogenic acid after oral administration of lonicerae japonicae flos and shuang-huang-lian in normal and febrile rats,” Phytotherapy Research, vol. 28, no. 1, pp. 144–147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Arimoto-Kobayashi, X. Zhang, Y. Yuhara, T. Kamiya, T. Negishi, and G. Okamoto, “Chemopreventive effects of the juice of Vitis coignetiae Pulliat on two-stage mouse skin carcinogenesis,” Nutrition and Cancer, vol. 65, no. 3, pp. 440–450, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Reitman and S. Frankel, “A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases,” The American Journal of Clinical Pathology, vol. 28, no. 1, pp. 56–63, 1957. View at Google Scholar · View at Scopus
  38. M. I. Walters and H. W. Gerarde, “An ultramicromethod for the determination of conjugated and total bilirubin in serum or plasma,” Microchemical Journal, vol. 15, no. 2, pp. 231–243, 1970. View at Publisher · View at Google Scholar · View at Scopus
  39. P. R. Kind and E. J. King, “Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine,” Journal of Clinical Pathology, vol. 7, no. 4, pp. 322–326, 1954. View at Publisher · View at Google Scholar · View at Scopus
  40. A. G. Gornall, C. J. Bardawill, and M. M. David, “Determination of serum proteins by means of the biuret reaction.,” The Journal of biological chemistry, vol. 177, no. 2, pp. 751–766, 1949. View at Google Scholar · View at Scopus
  41. F. Drupt, “Determination of serum albumin by bromocresol green,” Pharmaceutical Biology, vol. 8, pp. 77–99, 1974. View at Google Scholar
  42. A. L. Latner, “Clinical biochemistry,” in Cantarow and Trumper, pp. 147–259, W. B. Saunderss, Philadelphia, Pa, USA, 7th edition, 1975. View at Google Scholar
  43. C. C. Allain, L. S. Poon, C. S. Chan, W. Richmond, and P. C. Fu, “Enzymatic determination of total serum cholesterol,” Clinical Chemistry, vol. 20, no. 4, pp. 470–475, 1974. View at Google Scholar · View at Scopus
  44. D. Steinberg, “Metabolism of lipoproteins at the cellular level in relation to atherogenesis,” in Lipoproteins, Atherosclerosis and Coronary Heart Disease, vol. 1, pp. 2–11, 1981. View at Google Scholar
  45. P. Fossati and L. Prencipe, “Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide,” Clinical Chemistry, vol. 28, no. 10, pp. 2077–2080, 1982. View at Google Scholar · View at Scopus
  46. J.-. Fruchart, I. Kora, C. Cachera, V. Clavey, P. Duthilleul, and Y. Moschetto, “Simultaneous measurement of plasma apolipoproteins A-I and B by electroimmunoassay,” Clinical Chemistry, vol. 28, no. 1, pp. 59–62, 1982. View at Google Scholar · View at Scopus
  47. N. F. Suttle, “Copper deficiency in ruminants; recent developments,” Veterinary Record, vol. 119, no. 21, pp. 519–522, 1986. View at Publisher · View at Google Scholar · View at Scopus
  48. D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967. View at Google Scholar · View at Scopus
  49. H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hyroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Moshage, B. Kok, J. R. Huizenga, and P. L. M. Jansen, “Nitrite and nitrate determinations in plasma: a critical evaluation,” Clinical Chemistry, vol. 41, no. 6, pp. 892–896, 1995. View at Google Scholar · View at Scopus
  51. A. E. Ciarlone and J. W. Smudski, “Lidocaine's influence on the accumulation and depletion rates of mouse brain amines,” Journal of Dental Research, vol. 56, no. 11, pp. 1391–1394, 1977. View at Google Scholar · View at Scopus
  52. K. B. Burrows and B. K. Yamamoto, “Methamphetamine neurotoxicity: roles for glutamate, oxidative processes and metabolic stress,” in Glutamate and Addiction, B. H. Herman, Ed., pp. 211–227, Humana Press, Totowa, NJ, USA, 2003. View at Google Scholar
  53. J. L. Cadet, “Roles of glutamate, nitric oxide, oxidative stress, and apoptosis in the neurotoxicity of methamphetamine,” in Glutamate and Addiction, B. H. Herman, Ed., pp. 201–210, Humana Press, Totowa, NJ, USA, 2003. View at Google Scholar
  54. A. E. Fleckenstein, J. W. Gibb, and G. R. Hanson, “Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity,” European Journal of Pharmacology, vol. 406, no. 1, pp. 1–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Melo, L. G. Rodrigues, M. D. Pinazo-Durán, and M. A. Tavares, “Methamphetamine and lipid peroxidation in the rat retina,” Birth Defects Research A, vol. 73, no. 6, pp. 455–460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Giros, M. Jaber, S. R. Jones, R. M. Wightman, and M. G. Caron, “Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter,” Nature, vol. 379, no. 6566, pp. 606–612, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Stumm, J. Schlegel, T. Schäfer et al., “Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons,” The FASEB Journal, vol. 13, no. 9, pp. 1065–1072, 1999. View at Google Scholar · View at Scopus
  58. K. B. Burrows and B. K. Yamamoto, “Methamphetamine neurotoxicity: roles for glutamate, oxidative processes and metabolic stress,” in Glutamate and Addiction, B. H. Herman, Ed., pp. 211–227, Humana Press Inc, New Jersey, NJ, USA, 2003. View at Google Scholar
  59. P. Martin and L. S. Friedman, “Management of chronic liver-disease-Preface,” in Handbook of Liver Disease, L. Friedman and E. Keeffe, Eds., pp. 1–20, Churchill Livingstone, Philadelphia, Pa, USA, 1998. View at Google Scholar
  60. G. L. Plaa and W. R. Hewitt, “Detection and evaluation of chemical induced liver injury,” in Principles and Methods of Toxicology, W. A. Hayes, Ed., pp. 599–614, Raven Press, New York, NY, USA, 2nd edition, 1989. View at Google Scholar
  61. G. E. Gray and M. M. Meguid, “Can total parenteral nutrition reverse hypoalbuminemia in oncology patients?” Nutrition, vol. 6, no. 3, pp. 225–228, 1990. View at Google Scholar · View at Scopus
  62. J. V. Formica, “Review of the biology of quercetin and related bioflavonoids,” Food and Chemical Toxicology, vol. 33, no. 12, pp. 1061–1080, 1995. View at Publisher · View at Google Scholar · View at Scopus
  63. D. V. R. de Sotillo and M. Hadley, “Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats,” The Journal of Nutritional Biochemistry, vol. 13, no. 12, pp. 717–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Wan, C. N. Wong, W. Pin et al., “Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet,” Phytotherapy Research, vol. 27, no. 4, pp. 545–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Harnafi, M. Ramchoun, M. Tits et al., “Phenolic acid-rich extract of sweet basil restores cholesterol and triglycerides metabolism in high fat diet-fed mice: a comparison with fenofibrate,” Biomedicine and Preventive Nutrition, vol. 3, no. 4, pp. 393–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. K. M. M. Koriem, A. Z. Abdelhamid, and H. F. Younes, “Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats,” Toxicology Mechanisms and Methods, vol. 23, no. 2, pp. 134–143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Sato, S. Itagaki, T. Kurokawa et al., “In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid,” International Journal of Pharmaceutics, vol. 403, no. 1-2, pp. 136–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. J. Cejudo-Bastante, E. Durán-Guerrero, R. Natera-Marín, R. Castro-Mejías, and C. García-Barroso, “Characterisation of commercial aromatised vinegars: Phenolic compounds, volatile composition and antioxidant activity,” Journal of the Science of Food and Agriculture, vol. 93, no. 6, pp. 1284–1302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Huang, S. Lin, C. Chen, C. Pan, C. Lee, and H. Liu, “Oxidative stress status in recently abstinent methamphetamine abusers,” Psychiatry and Clinical Neurosciences, vol. 67, no. 2, pp. 92–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Melo, V. Zanon-Moreno, C. J. Alves et al., “Oxidative stress response in the adult rat retina and plasma after repeated administration of methamphetamine,” Neurochemistry International, vol. 56, no. 3, pp. 431–436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Ajjimaporn, S. Shavali, M. Ebadi, and P. Govitrapong, “Zinc rescues dopaminergic SK-N-SH cell lines from methamphetamine-induced toxicity,” Brain Research Bulletin, vol. 77, no. 6, pp. 361–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Solhi, A. Malekirad, A. M. Kazemifar, and F. Sharifi, “Oxidative stress and lipid peroxidation in prolonged users of methamphetamine,” Drug Metabolism Letters, vol. 7, no. 2, pp. 79–82, 2014. View at Google Scholar
  73. M. Teraoka, K. Nakaso, C. Kusumoto et al., “Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells,” Journal of Clinical Biochemistry and Nutrition, vol. 51, no. 2, pp. 122–127, 2012. View at Publisher · View at Google Scholar · View at Scopus